10X Lentivirus Yield With TFDF Perfusion: Scaling CAR-T Manufacturing Without Scaling the Bioreactor

Published on Repligen Application Note (Sept 2024)

Lentiviral vector production is a major bottleneck in CAR-T manufacturing, but TFDF-based perfusion is rapidly changing that. In this Repligen study, stable HEK293 producer cells cultured with TFDF achieved >10-fold higher LV output compared to batch. Notably, a 10 L TFDF-intensified process produced enough active virus for 100 patient doses, what would typically require a 200 L batch system. With continuous harvesting at 4°C, higher viability, and reduced footprint, this strategy simplifies and accelerates scale-up for Phase II/III trials.

Read the full application note from Repligen:

👉 Intensified Lentiviral Vector Production Using TFDF (PDF)

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.